CD47 Blockade Improves the Therapeutic Effect of Osimertinib in Non-small Cell Lung Cancer
Investigators explored a rational combination strategy for enhancing the osimertinib efficacy and found that it induced higher CD47 expression, an important anti-phagocytic immune checkpoint, via the NF-κB pathway.
[Prostate Cancer Foundation] The Prostate Cancer Foundation announced four inaugural Class of 2022 TACTICAL Award recipients. This $30 million program will support cross-disciplinary pioneering research toward the goal of developing 21st Century therapies for the most life-threatening form of prostate cancer.
[Nature Communications] Researchers reported high levels of androgen receptor chromatin binding heterogeneity in human primary prostate tumors, that overlapped with heterogeneity observed in healthy prostate epithelium.